Loading clinical trials...
Loading clinical trials...
A Multiple Dose, Open Label, Pivotal, 4 Period, 2 Treatment, Sequence Full Replicative Crossover Study to Assess the Bioequivalence (BE) of TEVA's Generic Once Daily Nevirapine 400 mg Prolonged Release (PR) Formulation Compared With the Approved Reference Product Viramune® 400 mg Prolonged Release Tablets Under Fasted Conditions in HIV1 Infected Patients
Conditions
Interventions
Nevirapine
Viramune®
Locations
1
United Kingdom
Chelsea and Westminster NHS Foundation Trust
London, United Kingdom
Start Date
August 1, 2014
Primary Completion Date
July 1, 2015
Completion Date
August 1, 2015
Last Updated
August 25, 2015
NCT07055451
NCT05136703
NCT05668026
NCT04174755
NCT06691321
NCT06631365
Lead Sponsor
Ratiopharm GmbH
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions